Titan Pharmaceuticals (TTNP) Competitors $5.02 +0.09 (+1.83%) Closing price 08/14/2025 03:57 PM EasternExtended Trading$4.96 -0.06 (-1.29%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock TTNP vs. NEUP, CYCC, MRKR, ALVR, AIMD, CTXR, LPTX, NXTC, IXHL, and PRPHShould you be buying Titan Pharmaceuticals stock or one of its competitors? The main competitors of Titan Pharmaceuticals include Neuphoria Therapeutics (NEUP), Cyclacel Pharmaceuticals (CYCC), Marker Therapeutics (MRKR), AlloVir (ALVR), Ainos (AIMD), Citius Pharmaceuticals (CTXR), Leap Therapeutics (LPTX), NextCure (NXTC), Incannex Healthcare (IXHL), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry. Titan Pharmaceuticals vs. Its Competitors Neuphoria Therapeutics Cyclacel Pharmaceuticals Marker Therapeutics AlloVir Ainos Citius Pharmaceuticals Leap Therapeutics NextCure Incannex Healthcare ProPhase Labs Neuphoria Therapeutics (NASDAQ:NEUP) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability. Which has better earnings & valuation, NEUP or TTNP? Titan Pharmaceuticals has higher revenue and earnings than Neuphoria Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuphoria Therapeutics$10K1,522.80-$15.49MN/AN/ATitan Pharmaceuticals$180K25.38-$4.71M-$4.59-1.09 Is NEUP or TTNP more profitable? Neuphoria Therapeutics' return on equity of 0.00% beat Titan Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Neuphoria TherapeuticsN/A N/A N/A Titan Pharmaceuticals N/A -145.92%-129.20% Do insiders & institutionals have more ownership in NEUP or TTNP? 15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are held by institutional investors. 0.7% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 0.7% of Titan Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, NEUP or TTNP? Neuphoria Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Does the media favor NEUP or TTNP? In the previous week, Titan Pharmaceuticals had 2 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 3 mentions for Titan Pharmaceuticals and 1 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 1.87 beat Titan Pharmaceuticals' score of 0.43 indicating that Neuphoria Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Neuphoria Therapeutics Very Positive Titan Pharmaceuticals Neutral Do analysts prefer NEUP or TTNP? Neuphoria Therapeutics currently has a consensus price target of $21.00, suggesting a potential upside of 159.26%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Neuphoria Therapeutics is more favorable than Titan Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Titan Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryNeuphoria Therapeutics beats Titan Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Titan Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TTNP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TTNP vs. The Competition Export to ExcelMetricTitan PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.51M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-1.0920.4930.2725.74Price / Sales25.38356.37469.95115.79Price / CashN/A43.0338.2159.48Price / Book1.888.608.846.15Net Income-$4.71M-$54.65M$3.25B$265.06M7 Day Performance28.88%5.86%3.71%2.60%1 Month Performance9.37%8.86%5.85%2.83%1 Year PerformanceN/A13.33%30.25%25.58% Titan Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TTNPTitan Pharmaceuticals0.2934 of 5 stars$5.02+1.8%N/A-8.7%$4.51M$180K-1.0910Earnings ReportShort Interest ↑Gap DownNEUPNeuphoria Therapeutics2.316 of 5 stars$7.20-3.1%$21.00+191.7%N/A$13.97M$10K0.00N/ACYCCCyclacel Pharmaceuticals1.2748 of 5 stars$9.05+3.1%N/A-97.4%$13.91M$40K-0.0114News CoveragePositive NewsEarnings ReportGap DownMRKRMarker Therapeutics3.8698 of 5 stars$1.19flat$13.17+1,006.4%-62.2%$13.47M$6.59M-0.8960Earnings ReportShort Interest ↑Gap UpALVRAlloVirN/A$2.67-1.5%N/A-86.6%$13.47MN/A-0.13110AIMDAinos0.9764 of 5 stars$3.26+2.5%N/A+5.3%$13.33M$20K-0.5140News CoverageEarnings ReportUpcoming EarningsShort Interest ↑CTXRCitius Pharmaceuticals2.8816 of 5 stars$1.25+1.6%$53.00+4,140.0%-91.1%$13.08MN/A0.0020News CoverageEarnings ReportAnalyst ForecastShort Interest ↓LPTXLeap Therapeutics2.4145 of 5 stars$0.31-1.1%$3.38+981.4%-90.1%$13.08MN/A-0.1840News CoverageEarnings ReportShort Interest ↓Gap DownNXTCNextCure4.2129 of 5 stars$4.80-1.4%$25.50+431.3%-72.1%$13.03MN/A-0.1990Short Interest ↑IXHLIncannex Healthcare0.3738 of 5 stars$0.45+1.0%N/A-78.6%$13.01M$10K-0.373Short Interest ↑PRPHProPhase Labs1.1052 of 5 stars$0.28-9.8%N/A-86.7%$12.97M$6.77M-0.22130Earnings ReportGap Down Related Companies and Tools Related Companies Neuphoria Therapeutics Alternatives Cyclacel Pharmaceuticals Alternatives Marker Therapeutics Alternatives AlloVir Alternatives Ainos Alternatives Citius Pharmaceuticals Alternatives Leap Therapeutics Alternatives NextCure Alternatives Incannex Healthcare Alternatives ProPhase Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TTNP) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access